FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912123790> ?p ?o ?g. }

• W2912123790 endingPage "A631" @default.
• W2912123790 startingPage "A631" @default.
• W2912123790 abstract "There were more than 200 million hypertension (HTN) patients in China. Uncontrolled HTN results in strokes, myocardial infarction (MI) and other complications, which are the leading cause of disability, death and severe economic consequence. We conducted an economic evaluation to determine the costs and quality-adjusted life years (QALYs) associated with Amlodipine (Norvasc) and the Angiotensin II Receptor Blockers (ARBs) in preventing stroke and MI among Chinese HTN patients. A cost-utility analysis was conducted from the third-party payer perspective. A Markov model was constructed to estimate five year costs and health consequences (12-month cycles). For each arm, 10,000 patients were included for the simulation with Valsartan as comparator. Effectiveness data on incidence of stroke and MI were based on a published meta-analysis. Relative risks of stroke and MI were 0.84 and 0.83 respectively comparing Amlodipine and ARBs. Utility data were retrieved from the published literature. Costs of MI were retrieved from Chinese government reimbursement database. Costs of stroke were obtained from retrospective chart review and follow-up interviews in Chinese tertiary hospitals. Costs included costs of drugs, direct medical costs of hypertension management, stroke/MI treatment, and follow-up management. Discounting rate used for costs and QALYs was 3%. Total direct medical and drug costs of Amlodipine and Valsartan users are ¥111,731,716 and ¥132,058,611 respectively; total QALYs of Amlodipine and Valsartan users are 30,648.5 and 30,520.8, respectively. Amlodipine is dominant with lower costs and higher QALYs. This demonstrated that, compared with Valsartan, Amlodipine is a cost saving therapy with increased overall survival due to the reduction in stroke and MI events. When Ibersartan data were used in the comparison, the magnitude of cost saving changed but overall conclusion remained the same. Amolodipine is a cost saving therapy compared with ARBs in preventing stroke and MI for Chinese hypertension patients." @default.
• W2912123790 created "2019-02-21" @default.
• W2912123790 creator A5001848487 @default.
• W2912123790 creator A5022571594 @default.
• W2912123790 creator A5025041754 @default.
• W2912123790 creator A5031340874 @default.
• W2912123790 creator A5039044405 @default.
• W2912123790 creator A5056171457 @default.
• W2912123790 creator A5073446766 @default.
• W2912123790 creator A5078082343 @default.
• W2912123790 date "2012-11-01" @default.
• W2912123790 modified "2023-10-05" @default.
• W2912123790 title "PCV15 A Cost-Effectiveness Analysis Between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention Among Hypertension Patients in China" @default.
• W2912123790 doi "https://doi.org/10.1016/j.jval.2012.08.185" @default.
• W2912123790 hasPublicationYear "2012" @default.
• W2912123790 type Work @default.
• W2912123790 sameAs 2912123790 @default.
• W2912123790 citedByCount "0" @default.
• W2912123790 crossrefType "journal-article" @default.
• W2912123790 hasAuthorship W2912123790A5001848487 @default.
• W2912123790 hasAuthorship W2912123790A5022571594 @default.
• W2912123790 hasAuthorship W2912123790A5025041754 @default.
• W2912123790 hasAuthorship W2912123790A5031340874 @default.
• W2912123790 hasAuthorship W2912123790A5039044405 @default.
• W2912123790 hasAuthorship W2912123790A5056171457 @default.
• W2912123790 hasAuthorship W2912123790A5073446766 @default.
• W2912123790 hasAuthorship W2912123790A5078082343 @default.
• W2912123790 hasBestOaLocation W29121237901 @default.
• W2912123790 hasConcept C126322002 @default.
• W2912123790 hasConcept C127413603 @default.
• W2912123790 hasConcept C194828623 @default.
• W2912123790 hasConcept C2777387769 @default.
• W2912123790 hasConcept C2779646130 @default.
• W2912123790 hasConcept C2780645631 @default.
• W2912123790 hasConcept C500558357 @default.
• W2912123790 hasConcept C71924100 @default.
• W2912123790 hasConcept C78519656 @default.
• W2912123790 hasConcept C84393581 @default.
• W2912123790 hasConceptScore W2912123790C126322002 @default.
• W2912123790 hasConceptScore W2912123790C127413603 @default.
• W2912123790 hasConceptScore W2912123790C194828623 @default.
• W2912123790 hasConceptScore W2912123790C2777387769 @default.
• W2912123790 hasConceptScore W2912123790C2779646130 @default.
• W2912123790 hasConceptScore W2912123790C2780645631 @default.
• W2912123790 hasConceptScore W2912123790C500558357 @default.
• W2912123790 hasConceptScore W2912123790C71924100 @default.
• W2912123790 hasConceptScore W2912123790C78519656 @default.
• W2912123790 hasConceptScore W2912123790C84393581 @default.
• W2912123790 hasIssue "7" @default.
• W2912123790 hasLocation W29121237901 @default.
• W2912123790 hasOpenAccess W2912123790 @default.
• W2912123790 hasPrimaryLocation W29121237901 @default.
• W2912123790 hasRelatedWork W1975929535 @default.
• W2912123790 hasRelatedWork W1989394631 @default.
• W2912123790 hasRelatedWork W2000308706 @default.
• W2912123790 hasRelatedWork W2060619242 @default.
• W2912123790 hasRelatedWork W2364750974 @default.
• W2912123790 hasRelatedWork W2371587947 @default.
• W2912123790 hasRelatedWork W2376706830 @default.
• W2912123790 hasRelatedWork W2389075477 @default.
• W2912123790 hasRelatedWork W2497668652 @default.
• W2912123790 hasRelatedWork W3026649645 @default.
• W2912123790 hasVolume "15" @default.
• W2912123790 isParatext "false" @default.
• W2912123790 isRetracted "false" @default.
• W2912123790 magId "2912123790" @default.
• W2912123790 workType "article" @default.